Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory facial tolerability study of CD5789 formulations in acne
2010-024214-54Phase 2Completed
- Sponsor
- Galderma
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of trifarotene in acne vulgaris (3 arms), sponsored by Galderma. Primary endpoints: Local tolerability and Subject adherence to treatment. Started Feb 2011; status: completed.
02
Drugs
trifarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2010-024214-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024214-54.